Acute Pain – Pipeline Review, 2025

The global acute pain pipeline has evolved and grown with the rising rate of incidence of diseases and growing safety apprehensions have propelled the inclination for searching for safer substitutes to accessible therapies, particularly opioids. Pain is a hurtful sensory and disturbing experience to an individual. It usually arises from actual or potential tissue damage caused by numerous events and circumstances. Acute pain is a complicated medical problem to analyze and treat.

The acute pain happens in a person who is suffering from rigorous pain and unable to get restful sleep as a consequence of losing their appetite. It can also cause breathing difficulties depending on the location of the pain. In a worst-case situation, patients may develop an addiction to pain medication or even depression. Analysis and treatment of the cause of pain is an indispensable phase of treatment. Initial treatment may comprise application of heat or ice, resting the affected part of the body, nonsteroidal anti-inflammatory drugs (NSAIDS) for instance aspirin, ibuprofen, or acetaminophen, or naproxen. Some other therapies consist of exercise and physical therapy. Therefore, these requirements for analyzing the causes and their treatment are pushing clinical researchers to work toward R&D activities for drug development and drug approval.

Acute Pain Pipeline Insights 2025: Report Scope

Covering 25+ pipeline drugs and 25+ companies, Fortune Business Insights has released its report “Acute Pain Pipeline Insight 2025”. It offers a deep-dive into both clinical and non-clinical stage acute pain pipeline drug profiles along with an assessment of acute pain pipeline therapeutics based on drug type, indication, and end-user. The report also offers an insight into the drug development and clinical research scenario across major regions. Further, it presents a preview of the current industry trends and key developments in the market. The report has also covered key regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Reasons to Buy this Report

• Develop strong business strategies based on a complete insight into acute pain pipeline products and R&D activity at the regional and global levels.
• Identify market rivalry and emerging companies in the field of acute pain technology and develop valuable strategies to outpace opponents.
• Understand what leading industry players highlight in relation to R&D initiatives focused on acute pain therapeutics.
• Recognize potential companies from the point of view of acquisitions and/or collaborations based on R&D activities.
• Develop valuable strategies for expanding R&D focus to endorse business growth
• Assess factors that are on the edge of discontinued and dormant products to make adjustments in R&D pivot, if required.

Know Answers to Your Questions

• What is the number of companies developing acute pain drugs?
• What are the numbers of acute pain drugs developed by each company?
• What are the numbers of emerging drugs in their Phase 2 trails, and Phase 3 trials of development for the treatment of acute pain?
• What are the major collaborations (industry-Academia and Industry-Industry), mergers and acquisitions, licensing activities associated to the acute pain therapeutics?
• What are the latest trends, drug types and novel technologies developed to surmount the constraint of existing therapies?
• What are the clinical studies under way for acute pain and their statuses?
• What are the major designations that have been granted to the coming drugs?

Report Methodology

• These pipeline reports are created through concentrated analysis of data. These data are primarily taken from credible desk research sources. Conducting interviews with key opinion experts forms the secondary source of data research.
• The desk research sources cover regional and global databases. These databases include clinical trials, annual reports, websites, press releases of companies and investor presentations, white papers, and news articles. Some other sources are internal databases, reports published by industry associations, and reports/articles published on databases such as ResearchGate and NCBI, among others.

Clinical Trial Insights

The growing demand for effective therapeutic solutions for acute pain treatment is strengthening the acute pain drug R&D perspectives. Various healthcare institutes, research organizations, and medical industry players are producing new drugs by performing clinical trials. The growing focus of government bodies for enhancing their healthcare infrastructure is further supporting the global clinical trial scenario in the field of acute pain therapy.

Acute Pain Pipeline Overview

Favorable government guidelines and escalating acute pain awareness activities have supported product development initiatives. A number of new drug candidates are in their preclinical and discovery stages. They are also in going through Phase 1, Phase 2, and Phase 3 trials. Companies are joining forces and forming acquisitions for receiving funds to advance their process of drug development. Healthcare majors are also keen to get their drug approved from regulatory bodies for instance the U.S. FDA (Food and Drug Administration) for bringing their candidates to the market.

Brief insights regarding the upcoming drugs in pipeline are as below:

NTM-001: Neumentum

NTM-001 is the lead product candidate of Neumentum. It is a new non-alcohol formulation of the strong NSAID ketorolac. It is designed in a pre-mixed bag for 24-hours of constant infusion subsequent surgery. It is evaluated as a moderately managed medicine for severe acute pain, which requires analgesia at the opioid-level and generally in a postoperative setting.

CGT 1507:CGeneTech

Otenaproxesul is a new nonsteroidal anti-inflammatory drug (“NSAID”). It releases hydrogen sulfide. Antibes is utilizing the potency of this drug for gastrointestinal (“GI”) safety and overall protection profiles that can be used in acute pain indications. It is being produced for post-operative pain as a safer non-opioid analgesic.

TRPA1 Antagonist: Algomedix

Algomedix has created a non-addictive and a non-opioid modern TRPA1 antagonist. It is utilized for the cure of chronic and acute pain. This drug is emphasizing on the making of a novel small molecule TRPA1 antagonist. This clinical candidate presents the potential for next-generation palliative devoid of the addiction and mistreatment liabilities and other undesirable effects innate in the opioid class of drugs.